You're not logged in. Please log in to earn stock or Bitcoin rewards on your prescription purchase.
Varubi (180 MG Dose)
Varubi (generic name: rolapitant) is a neurokinin-1 (NK-1) receptor antagonist used to prevent delayed nausea and vomiting associated with chemotherapy. It is usually given as part of a combination therapy with other anti-nausea medications like 5-HT3 receptor antagonists and corticosteroids. Varubi works by blocking the activity of the NK-1 receptors in the brain, which are involved in triggering nausea and vomiting during chemotherapy. The 180 mg dose is typically used in adults receiving chemotherapy that has a high or moderate risk of causing nausea and vomiting.
Rx. Enter your prescription
How would you like to get your prescription? Select an option
Pharmacy pickup
Select from 35,000 pharmacies
Free two-day delivery
Coming soon!
Find a pharmacy near you. Enter your ZIP code
Are you a member? Sign up or log in.
Members have saved
$NaN
using our savings card for instant savings.
Don't pay full retail price and miss out on potential savings. Try it now—you have nothing to lose!
NaNM
worth of Satoshi has been rewarded to our members.
Everyone who signs up enjoys the benefits of earning FREE Bitcoin with every purchase.
How much Bitcoin can you earn with Varubi (180 MG Dose) ?
The potential for Bitcoin rewards to increase and appreciate in value is a possibility to consider, which may occur over time.
See the value of your savings today
Today's Value
1 Bitcoin = $NaN
Bitcoin (BTC)
...
USD
$NaN
Adjust Bitcoin's potential value to see how much it could be worth
Potential Value
1 Bitcoin =
Bitcoin (BTC)
...
USD
$NaN
Frequently Asked Questions
How long does Varubi work after taking a dose?
Varubi has a long half-life and can work for up to 120 hours (5 days) after a single dose to prevent delayed nausea and vomiting.
Can I take Varubi more than once during my chemotherapy cycle?
No, Varubi is typically given only once per chemotherapy cycle, usually on Day 1, and should not be taken more than once every 14 days.
Can I take Varubi with other anti-nausea medications?
Yes, Varubi is often used in combination with 5-HT3 receptor antagonists (e.g., ondansetron) and corticosteroids (e.g., dexamethasone) to provide comprehensive protection against chemotherapy-induced nausea and vomiting.
Does Varubi have any food restrictions?
No, Varubi can be taken with or without food. Follow your healthcare provider's instructions on timing the dose in relation to chemotherapy.
Does Varubi interact with over-the-counter medications?
Varubi may interact with certain over-the-counter medications, especially those metabolized by CYP2D6. Always inform your healthcare provider of all medications you are taking, including over-the-counter drugs.
Comprehensive Drug Guide
How Does Varubi (180 MG Dose) Work?
Varubi works by blocking neurokinin-1 (NK-1) receptors in the brain, which play a key role in the body's response to nausea and vomiting triggered by chemotherapy. By preventing the activation of these receptors, Varubi helps reduce the incidence of delayed chemotherapy-induced nausea and vomiting (CINV), which typically occurs 24 to 120 hours after chemotherapy.
Common Dosages
- 180 mg oral tablets
Typical Dosing
- The typical dose of Varubi is 180 mg (one tablet) taken orally approximately 1 to 2 hours before chemotherapy on Day 1 of treatment.
- Varubi is not taken on subsequent days of the chemotherapy cycle. It is given only on Day 1 and should not be administered more than once every 14 days.
Typical Dosing
FDA Approved Indications
- Prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic and highly emetogenic chemotherapy in adults.
Who Shouldn't Take Varubi (180 MG Dose)?
- Known hypersensitivity to rolapitant or any components of the formulation.
- Use with thioridazine, as Varubi can increase the levels of this medication and lead to potentially serious heart problems.
Advice From The Pharmacist
- Take Varubi with or without food about 1 to 2 hours before starting chemotherapy. Follow your doctor’s instructions closely regarding the timing of Varubi in combination with other anti-nausea medications.
- Varubi has a long duration of action and is designed to prevent delayed nausea and vomiting. If you experience nausea immediately after chemotherapy, consult your healthcare provider, as additional medications may be necessary.
- Do not take more than the prescribed dose or use it more frequently than directed, as Varubi is typically administered only once per chemotherapy cycle.
Side Effects of Varubi (180 MG Dose)
Common Side Effects
- Fatigue
- Loss of appetite
- Dizziness
- Hiccups
- Abdominal pain
Uncommon/Severe Side Effects
- Hypersensitivity reactions (rash, itching, swelling, difficulty breathing).
- QT prolongation, especially when used with other medications that affect heart rhythm.
Risks and Warnings of Varubi (180 MG Dose)
- QT Prolongation: Varubi may increase the risk of QT interval prolongation, which can lead to abnormal heart rhythms. Use caution in patients with a history of heart conditions or those taking medications known to affect heart rhythm.
- Drug Interactions: Varubi may interact with a variety of medications, including CYP2D6 substrates (e.g., thioridazine), leading to increased blood levels of those medications. Always inform your healthcare provider of all medications you are taking.
Interactions with Varubi (180 MG Dose)
Common Drug Interactions
- Thioridazine: Concurrent use with Varubi is contraindicated due to the risk of severe QT prolongation.
- CYP2D6 substrates (e.g., codeine, metoprolol): Varubi may increase the blood levels of these medications, increasing the risk of side effects.
- Warfarin: Varubi may affect the metabolism of warfarin, potentially increasing its effects. Regular monitoring of INR (International Normalized Ratio) is recommended when used together.
Alternatives to Varubi (180 MG Dose)
- Aprepitant (Emend): Another NK-1 receptor antagonist used to prevent chemotherapy-induced nausea and vomiting.
- Fosaprepitant: The intravenous form of aprepitant, used for preventing CINV.
- Ondansetron (Zofran): A 5-HT3 receptor antagonist commonly used in combination with NK-1 receptor antagonists to prevent nausea and vomiting.
